Yazılar

FDA to Review AI-Powered Mental Health Devices in November Advisory Panel

/in /tarafından

The U.S. Food and Drug Administration (FDA) announced it will convene its Digital Health Advisory Committee (DHAC) on November 6 to evaluate the growing category of AI-enabled digital mental health tools.

The meeting will explore how technologies such as chatbots, virtual therapists, and digital therapeutics could help bridge the nation’s mental health care gap, while also assessing the risks of safety, efficacy, and oversight.

Why It Matters

The U.S. faces a shortage of mental health professionals, and AI-driven platforms promise scalability, accessibility, and rapid intervention. But the speed of innovation has left regulators searching for frameworks to ensure these devices are trustworthy and clinically sound.

FDA’s Approach

  • The DHAC will advise the agency on regulatory pathways for AI/ML tools, remote monitoring, digital therapeutics, and medical device software.

  • The panel discussion is expected to help the FDA identify key areas of concern such as data privacy, bias in algorithms, and standards for clinical validation.

  • The FDA has already begun experimenting with AI in its review processes, reflecting its broader shift toward digital oversight.

Next Steps

  • The FDA has opened a public docket for comments ahead of the session.

  • Supporting materials will be made available at least two business days before the meeting.

The November discussion could shape how future AI mental health devices are classified, monitored, and approved in the U.S., setting an early precedent for regulation in this rapidly expanding sector.

Philips Faces French Criminal Probe Over Sleep Apnea Device Recall

/in /tarafından

Paris prosecutors have opened a criminal investigation into Philips (PHG.AS) over its 2021 recall of sleep apnea machines, examining potential charges of aggravated fraud and failure to report safety risks that could lead to death.

The recall affected 15 million devices worldwide, including 350,000 in France, after it was discovered that polyurethane foam inside the machines could degrade, releasing particles or gases linked to headaches, respiratory issues, and even cancer risks.

The Paris Public Health division confirmed receiving 104 individual complaints tied to the devices. The probe was formally launched on June 12 after a preliminary inquiry by France’s OCLAESP (Central Office for the Fight against Environmental and Public Health Damage).

Philips stressed that this is not a new investigation, but part of ongoing proceedings initiated in 2023 concerning the lead-up to the recall. The company said the case does not concern products currently sold in France and pledged to cooperate with judicial authorities.

Under French law, aggravated fraud endangering human health carries penalties of up to seven years in prison and €750,000 in fines for individuals, and up to €3.75 million for corporations.

The case adds to Philips’ global legal woes. In 2023, the company agreed to a $1.1 billion settlement in the U.S. related to the same recall. Shares fell nearly 5% in early trading Monday before trimming losses to -1% by 1400 GMT following confirmation of the French probe.

New Patch Technology Uses Electricity to Fight Harmful Skin Bacteria

/in /tarafından

Scientists have developed a groundbreaking patch that uses mild electrical pulses to combat harmful bacteria on the skin. The Bioelectronic Localized Antimicrobial Stimulation Therapy (BLAST) patch is designed to help prevent infections by targeting bacteria that could potentially enter the bloodstream and cause severe health issues. This innovative approach leverages harmless electrical currents to disrupt the bacteria’s ability to adhere to skin surfaces, offering a new way to address skin infections at their source.

The BLAST patch has shown promising results in recent trials conducted on pig skin, which closely resembles human skin in structure and is commonly used in preclinical studies. During these tests, the researchers applied Staphylococcus epidermidis bacteria, a microorganism normally found on human skin that usually poses no threat. However, when this bacteria is introduced into the body through medical devices like catheters, it can lead to infections that are difficult to treat.

In the experiment, the BLAST patch was placed on the pig skin, and mild electrical pulses were delivered every ten minutes over an 18-hour period. These pulses, similar in intensity to those used in pacemakers, effectively reduced the formation of biofilms—protective layers that allow bacteria to resist treatment. The results were striking, showing a nearly tenfold reduction in bacterial levels on the treated skin, suggesting that the patch could be an effective method for reducing bacterial presence and the risk of infection.

With the success of these tests, the BLAST patch offers a promising new avenue for tackling skin infections, particularly in healthcare settings where the risk of bacterial transmission is high. This bioelectronic device could complement traditional antibiotic treatments, providing a non-invasive, localized solution to control harmful bacteria before they spread. The next steps will likely involve further clinical testing, with the hope that the BLAST patch could soon become a valuable tool in preventing infections and improving patient outcomes.